Abstract
Discrimination of idiopathic inflammatory myopathy (IIM) from other muscle diseases is at times difficult in clinical practice even after muscle biopsy.1 Acknowledgment: The authors thank Hiromi Yamaguchi (Department of Immunology, National Institute of Neuroscience [NIN], NCNP), Kanako Goto (Department of Neuromuscular Research, NIN, NCNP), and Dr. Shigeaki Suzuki (Department of Neurology, Keio University School of Medicine) for support.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
